McNicoll Lewis & Vlak Starts Prana Biotechnology (PRAN) at Buy; Novel Therapeutic Approach to CNS Disorders: Neuronal Metal Homeostasis
PRAN Hot Sheet
Rating Summary:1 Buy, 0 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 16 | Down: 7 | New: 23
McNicoll Lewis & Vlak initiates coverage on Prana Biotechnology (NASDAQ: PRAN) with a Buy. PT $6.00.
MLV analyst says, "Prana is an early stage, neurologically focused biotechnology company focused on the discovery and development of treatments for Alzheimer’s disease (AD), Huntington’s disease (HD), and other major CNS disorders. We would own the stock for several reasons, including: 1) recent data that elucidates the mechanism 2) strong Phase II data in AD 3) aging US population 4) lack of disease modifying agents, and 5) billion dollar revenue potential."
For more ratings news on Prana Biotechnology click here and for the rating history of Prana Biotechnology click here.
Shares of Prana Biotechnology closed at $1.40 yesterday, with a 52 week range of $1.13-$4.50.
Discover Wall Street's best ratings calls with the pros - Upgrade to Ratings Insider Elite. Free Trial!
MLV analyst says, "Prana is an early stage, neurologically focused biotechnology company focused on the discovery and development of treatments for Alzheimer’s disease (AD), Huntington’s disease (HD), and other major CNS disorders. We would own the stock for several reasons, including: 1) recent data that elucidates the mechanism 2) strong Phase II data in AD 3) aging US population 4) lack of disease modifying agents, and 5) billion dollar revenue potential."
For more ratings news on Prana Biotechnology click here and for the rating history of Prana Biotechnology click here.
Shares of Prana Biotechnology closed at $1.40 yesterday, with a 52 week range of $1.13-$4.50.
Discover Wall Street's best ratings calls with the pros - Upgrade to Ratings Insider Elite. Free Trial!
You May Also Be Interested In
- UPDATE: William Blair Starts EPIQ Systems (EPIQ) at Outperform; Broad Suite of Solutions in Electronic Discovery Sector
- Nomura Securities Maintains a 'Neutral' on Tiffany & Co. (TIF); Cutting Estimates and Price Target
- UBS Maintains a 'Neutral' on Patterson Companies (PDCO); Raising 'The Bar' and Estimates
Create E-mail Alert Related Categories
New CoverageSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
